| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.45 | 0.1 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.1 |